Your browser doesn't support javascript.
loading
Decreasing cholesterol levels in the community--lifestyle change with statin?
Savolainen, Jorma; Kautiainen, Hannu; Niskanen, Leo; Mäntyselkä, Pekka.
Afiliação
  • Savolainen J; Institute of Public Health and Clinical Nutrition, Primary Health Care, School of Medicine, University of Eastern Finland, P.O. Box 1627, FI-70211, Kuopio, Finland. Jorma.Savolainen@uef.fi.
  • Kautiainen H; Primary Health Care Unit, Kuopio University Hospital, P.O. Box 100, FI-72009 KYS, Kuopio, Finland. Jorma.Savolainen@uef.fi.
  • Niskanen L; Department of General Practice, Helsinki University Central Hospital, Unit of Primary Health Care and University of Helsinki, P.O. Box 20, FI-00014, Helsinki, Finland. Hannu.Kautiainen@medcare.fi.
  • Mäntyselkä P; Endocrinology, Abdominal Center, Helsinki University Central Hospital, P.O. Box 55, FI- 00014, Helsinki, Finland. Leo.Niskanen@hus.fi.
BMC Fam Pract ; 16: 29, 2015 Feb 28.
Article em En | MEDLINE | ID: mdl-25879518
ABSTRACT

BACKGROUND:

The Lapinlahti 2005-2010 study was carried out to explore cardiovascular disease risk factors and changes in lifestyle in Lapinlahti residents in eastern Finland. Our aim was to analyse factors influencing the level of cholesterol in the community.

METHODS:

In 2005, 480 subjects aged 30-65 years underwent a complete health survey (baseline study) that consisted of a structured questionnaire and a health examination. The follow-up was carried out five years later in 2010. The present study population included 326 individuals who did not use lipid-lowering medication at the baseline. A trained research nurse measured weight, height, waist circumference and blood pressure at the baseline and follow-up. Respectively, lifestyle factors (nutrition, exercise, smoking and alcohol use) were examined with a structured questionnaire. Each lifestyle item was valued as -1, 0 or 1, depending on how closely it fitted to the recommendations. Cholesterol level analyses at the baseline and follow-up were performed according to the protocol of the Kuopio University Hospital's medical laboratory. Based on their baseline cholesterol levels, the participants were divided into tertiles. The age- and sex-adjusted linear trend between the tertiles was tested.

RESULTS:

The change in cholesterol level was associated with lipid-lowering medication (P < 0.001). Lifestyle improvement was associated with the cholesterol level change but did not reach statistical significance (P = 0.061), although the interaction of lipid-lowering medication and lifestyle change was associated with the change in cholesterol level (P = 0.018). In multivariate analysis, a favourable change in fat consumption (P = 0.007) and lipid-lowering medication (P < 0.001) were associated with decreasing cholesterol levels.

CONCLUSIONS:

At the population level, dyslipidaemia is one of the most easily modifiable risk factors of CHD. Lipid-lowering medication may have the most significant impact on cholesterol level in communities with primary health care with good coverage. On the other hand, the potential of health-promoting and population-based prevention strategies may be underused.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Colesterol / Inibidores de Hidroximetilglutaril-CoA Redutases / Dislipidemias / Estilo de Vida Tipo de estudo: Diagnostic_studies / Etiology_studies / Qualitative_research / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Colesterol / Inibidores de Hidroximetilglutaril-CoA Redutases / Dislipidemias / Estilo de Vida Tipo de estudo: Diagnostic_studies / Etiology_studies / Qualitative_research / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2015 Tipo de documento: Article